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Variation in the insulin responsive element (IRE) of the APOC3 promoter has been shown to be associated with insulin and glucose
concentrations after an oral glucose tolerance test (OGTT) in young healthy men. We evaluated two variants in the IRE ( 455T>C and
 482C>T) in the Ely study, a prospective cohort study of middle-aged men (n = 223) and women (n = 279), to determine if the effect of these
variants on glucose homeostasis could be explained by altered nonesterified fatty acid (NEFA) levels and if these effects are modulated by
age and gender. Both variants had significant effects on the 30-min insulin incremental response in men alone ( 482C>T, P= 0.007;
 455T>C, P= 0.0155), with rare allele homozygotes having a 33.3% and 23.3% lower insulin increment as compared to common allele
homozygotes, respectively. Thirty-minute NEFA concentrations were also significantly associated with genotype in men and levels were
approximately 10% higher in carriers homozygous for the rare alleles as compared to subjects homozygous for the common alleles
( 482C>T, P= 0.04;  455T>C, P= 0.006). In addition, there was a strong interaction between both variants and cigarette smoking affecting
fasting triglyceride levels in both men (interaction:  455T>C, P= 0.02;  482C>T, P= 0.008) and women (interaction:  455T>C,
P= 0.007;  482C>T, P= 0.013). Taken together, the data shows that men who carry the rare alleles of the IRE variants have disturbed
glucose homeostasis and an unfavourable lipid phenotype. The finding of an elevated 30-min NEFA may be an important mechanistic link
between triglyceride-rich lipoprotein (TRL) metabolism and glucose homeostasis.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Glucose homeostasis; Nonesterified fatty acid; Triglyceride metabolism; Atherosclerosis; Type 2 diabetes
1. Introduction oprotein genes have generally not been investigated asWe have previously shown that a variant in the APOC3
promoter, a gene primarily known to be involved in trigly-
ceride-rich lipoprotein (TRL) metabolism, is also associated
with insulin and glucose levels after an oral glucose toler-
ance test (OGTT) in young healthy men [1]. These findings
demonstrate some of the interactions between lipid and
glucose metabolism and support the involvement of lipid
metabolism in the development of type 2 diabetes. Lip-0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00021-8
Abbreviations: IRE, insulin responsive element; OGTT, oral glucose
tolerance test; NEFA, nonesterified fatty acids; TRL, triglyceride-rich
lipoproteins; APOC3, apolipoprotein CIII gene
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E-mail address: dawn.m.waterworth@gsk.com (D.M. Waterworth).candidate genes for type 2 diabetes, though one report has
implicated the APOA1–C3–A4 locus in determining risk,
but only in overweight individuals [2].
ApoCIII is a 79-aa glycoprotein, synthesized by the liver
and small intestine and is a major protein component of TRL
and HDL. Epidemiological studies have shown that plasma
levels of apoCIII, and the distribution of apoCIII between
plasma lipoprotein fractions, appear to be important in the
progression of coronary artery disease (CAD) [3,4]. Trans-
genic mouse studies have suggested that the predominant
mechanism of apoCIII-induced hypertriglyceridaemia was
decreased lipolysis at the cell surface [5]. Thus, apoCIII
probably impacts on CAD by inhibiting lipoprotein lipase-
mediated lipolysis and prolonging of the exposure time of the
arterial wall to atherogenic particles such as very-low-density
lipoproteins (VLDL) and remnant particles.ed.
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11q23.3 [6] and is flanked by the genes for APOA1, APO4
and APOA5 in a 50-kb gene cluster [7]. Two variants
( 455T>C and  482C>T) occur within the insulin
responsive element (IRE) in the APOC3 promoter. ApoCIII
expression is normally down-regulated 40–50% by insulin,
and the presence of a rare allele of either variant ( 455C
or  482T) proved sufficient to remove the ability of insulin
to inhibit apoCIII expression in vitro [8]. However, we have
shown that the  482C>T [1], but not  455T>C (unpub-
lished data), significantly influences insulin and glucose
levels after an OGTT in young healthy men from the
EARSII study. Subjects who carried the  482T allele had
significantly elevated AUC insulin and glucose concentra-
tions as compared to  482CC subjects.
The aim of this study was to establish if the effect of
APOC3 promoter variants on insulin and glucose measures
was exaggerated or altered in middle-aged men and women,
a population in which impaired glucose tolerance and
dyslipidemia should be more prevalent. Thus, while results
from EARSII reflected the effects in healthy young men, the
Ely study enabled us to examine these effects in both men
and women in middle age. Furthermore, we had hypothe-
sized that apoCIII may be affecting glucose metabolism by
causing elevated nonesterified fatty acid (NEFA) levels, and
NEFA measures were available in this cohort.2. Material and methods
2.1. Sample population
The Ely Study is a prospective population-based study of
the aetiology and pathogenesis of type 2 diabetes mellitus
and related disorders that has been described previously
[9,10]. Briefly, subjects who were not known to have
diabetes were randomly recruited from a sampling frame
consisting of all those aged 40–65 years in the single GP
practice in Ely, Cambridgeshire, in April 1990 [10]. Sub-
jects (n = 1122; 74% response rate) agreed to participate and
attended the local surgery after a 10 h fast for a clinical
examination, which included a dietary and medical ques-
tionnaire, anthropometric measurements and a standard 75 g
OGTT (blood drawn at 0, 30 and 120 min). Fifty-one
subjects had prevalent but undiagnosed diabetes. The
remaining 1071 nondiabetic subjects were followed up 4.5
years later [9] and 937 individuals underwent the same
evaluation as in 1990–1992. The data presented in this
paper is on a random subgroup of 502 individuals who had
complete data at both phases of the Ely Study and on whom
a DNA sample was available.
2.2. Biochemical measures
All blood samples were immediately placed on ice and
centrifuged on site. Serum samples were aliquoted, packedin ice and transferred to the laboratory where they were
stored at  70 jC within 4 h. Plasma glucose was measured
using the hexokinase method [11] and triglyceride measured
using the RA 1000 (Bayer Diagnostics, Basingstoke, UK)
with a standard enzymatic method. Plasma insulin was
determined by two-site immunometric assays with either
125I or alkaline phosphatase labels [12,13]. Plasma NEFA
were determined enzymatically based on acyl-CoA synthe-
tase activity (Boehringer Mannheim, Lewes, Sussex, UK)
[14].
2.3. Polymorphism detection
Both variants analysed were restriction fragment length
polymorphisms (RFLP) and the  482C>T assay was
performed as described previously [1]. The same PCR
product (as the  482C>T) was digested with 1 unit of
Fnu4HI (NEB) at 37 jC overnight to determine the
 455T>C variant. The fragments were separated by using
5–10% polyacrylamide Microtitre Array Diagonal Gel
Electrophoresis (MADGE) [15].
2.4. Statistical analysis
The data presented are from both phases of the study
with an average of 4.5 years of follow-up. T-tests were used
to compare characteristics and biochemical measures
between men and women at baseline. The 30-min insulin
incremental response (a measure of insulin secretion) was
calculated by dividing the difference between 30 min and
fasting insulin concentrations by the 30-min glucose con-
centration [9]. We hypothesized that a gene effect would
determine the ‘usual’ level of insulin sensitivity, which
could be estimated by repeated measurement. We did not
hypothesize that the APOC3 polymorphisms would affect
the rate of change of insulin sensitivity over time, as such an
analysis would probably require the use of a larger pop-
ulation, a longer follow-up and a more precise measure of
insulin sensitivity. In this study, the primary outcome
variables were insulin/glucose and NEFA levels following
an OGTT and also the 30-min insulin increment, which
combines the insulin and glucose measures to generate an
estimate of insulin secretion and should be more informative
than either insulin and glucose alone. A mixed model using
outcome variables from both phases of the study was used
to describe the differences between genotypes with time-
dependent (e.g. body mass index) and fixed covariates
(sex). The MIXED procedure in SAS was used for this
analysis, which allows repeated measures for each subject
and avoids the loss of subjects due to missing data points
(SAS Institute Inc., Release 6.12, Cary, NC, USA). Traits
that were not normally distributed, e.g. insulin and trigly-
ceride, were normalized using log transformation. We also
examined possible interaction effects between genotype and
smoking in the MIXED analysis for each variable of
interest.
Table 2
Adjusted means (S.D.) for the 30-min insulin incremental response by
APOC3  482C>T (n= 502) and APOC3  455T>C (n= 499) genotype
using data from both phases of the Ely Study
Men Women
N Mean 95% CI N Mean 95% CI
Lower Upper Lower Upper
 482TT 136 26.91 24.75 29.27 149 31.01 28.54 33.68
 482CT 72 28.27 25.21 31.70 103 29.47 26.68 32.56
 482CC 15 18.05 14.00 23.27 27 26.74 21.96 32.55
P value 0.007 0.359
 455CC 91 27.53 24.84 30.52 104 30.27 27.38 33.47
 455TC 97 27.97 25.32 30.89 132 29.99 27.40 32.75
 455TT 33 21.12 17.80 25.05 38 29.06 24.60 34.33
P value 0.0155 0.92
Data computed using mixed model analysis with 30-min insulin
incremental response (at both phases) as outcome variable, adjusted for
age and BMI.
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3.1. General characteristics
The general baseline characteristics and biochemical
measures of the sample stratified by sex are shown in Table
1. Significant differences between men and women are
shown.
The two variants in the IRE ( 482C>T and  455T>C)
were typed in all subjects and were found to be in Hardy–
Weinberg equilibrium. No other APOC3 variants were typed
in this cohort. The  482T allele frequency was 0.25 (95%
CI, 0.23–0.29) and the  455C allele frequency was 0.37
(95% CI, 0.34–0.39) in the total sample. The two variants
were in strong allelic association (D = 0.73, P < 0.001).
There was no significant difference in either  482T or
 455C allele frequencies by glucose tolerance status (nor-
mal glucose tolerance, impaired glucose tolerance or type 2
diabetes at follow-up) (data not shown).
3.2. Effects of APOC3 variants on insulin and glucose
measures
Multivariate regression models were constructed and
used to test for significant effects of each variant on both
fasting insulin (a surrogate for insulin sensitivity) and for the
30-min insulin incremental response (a surrogate for insulinTable 1
Baseline means (S.E.) or 95% confidence interval, characteristics and
biochemical measures of the sample group
Men Women
n 223 279
Age (years) 54.33 (0.52) 52.86 (0.45)a
Body mass index (kg/m2) 25.81 (0.18) 25.53 (0.28)
Waist-to-hip ratio 0.905 (0.004) 0.761 (0.003)b
Fasting NEFA (mmol/l) 0.405 (0.014) 0.524 (0.016)b
30-min NEFA (mmol/l) 0.404 (0.015) 0.429 (0.016)
120-min NEFA (mmol/l) 0.090 (0.005) 0.078 (0.003)a
NEFA area (mmol h/l) 0.561 (0.018) 0.620 (0.020)a
Fasting insulin (pmol/l)c 38.5 (35.7, 41.6) 40.1 (37.4, 43.0)
30-min insulin (pmol/l)c 241.1 (218.6, 266.0) 263.5 (244.4, 284.1)
120-min insulin (pmol/l)c 207.6 (186.4, 231.3) 230.2 (212.8, 249.2)
Insulin incrementc,d 23.6 (21.3, 26.1) 26.7 (24.3, 29.4)
log(FU insulin area)c 448.1 (414.0, 485.0) 473.6 (444.3, 504.9)
Fasting glucose (mmol/l)c 5.84 (5.77, 5.91) 5.57 (5.50, 5.63)b
30-min glucose (mmol/l)c 8.49 (8.28, 8.71) 7.80 (7.61, 7.98)b
120-min glucose (mmol/l)c 6.01 (5.78, 6.25) 6.08 (5.86, 6.30)
Glucose area (mmol h/l)c 14.61 (14.28, 14.94) 13.86 (13.55, 14.18)e
Fasting triglyceride (mmol/l)c 1.31 (1.22, 1.40) 1.10 (1.04, 1.16)b
Diabetes (%) 0 0
IGT (%) 21.5 25.8
Data are arithmetic mean (S.E.).
a PV 0.05.
b PV 0.001 (men vs. women).
c Data are geometric mean (95% CI).
d Insulin increment is the 30-min insulin incremental response (pmol/l
insulin/mmol/l glucose).
e PV 0.01.secretion) using both measures from each subject. No
significant effects on fasting insulin were found with either
variant in men or women. However, significant effects were
observed on the 30-min insulin incremental response (30-
min fasting insulin/30-min glucose) with both variants in the
men alone (Table 2). With both variants, the lowering effect
was confined to the rare allele homozygotes, but the
magnitude ( 482T/T vs. C/C, 33.3% lower;  455C/C
vs. T/T, 23.3% lower) of the effect was greater and the level
of statistical evidence better with the  482C>T variant as
compared to the  455T>C (P= 0.007 and P= 0.016,
respectively), though there was not sufficient statistical
evidence to suggest that the  482C>T was responsible
for this effect alone. There was no association found in
women for either variant.
Further insight into the relationship between  482C>T
and insulin and glucose over the course of the OGTT and
the gender difference observed in these parameters can be
seen in the separate plots of insulin and glucose in Fig. 1.
Plots for the  455T>C were similar to those shown, but
differences between genotype were less marked than for the
 482C>T and are not shown. It can be seen that the
reduced 30-min insulin secretion in male  482T/T carriers
is followed by an increase in insulin levels over the
remaining 90 min of the test, as compared to  482C
carriers who show a gradual decrease in insulin levels
(Fig. 1A). This is combined with an elevated glucose level
from 30 to 120 min in  482T/T male subjects as compared
to  482C carriers (AUC, P= 0.012). This explains why
 482T/T male subjects have a reduced 30-min insulin
increment (which incorporates 30-min glucose level),
despite the fact that 30-min insulin was not significantly
different by genotype alone. Women who carry the  482T/
T genotype show some reduction in insulin levels at 30 min,
but in contrast to the men, this is followed by a gradual
decrease in insulin levels in parallel to the  482C carriers,
an effect which is significant for AUC insulin (P= 0.028).
Fig. 1. Insulin (A), glucose (B) and NEFA (C) levels over the course of the OGTT in men and women, according to APOC3  482 genotype. (.) CC; (n) CT;
(E) TT. P values shown are for TT vs. CT+CC groups for AUC insulin/glucose/NEFA.
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genotype, explaining why a significant effect on 30-min
insulin incremental response (30-min fasting insulin/30-min
glucose) was not found in women (Fig. 1B).
3.3. Effects of APOC3 variants on lipid parameters
Significant effects were observed with both the  482C>
T and the  455T>C variants on serum fasting triglyceride,
but these effects were dependent on smoking status. Ad-
justed means by  482C>T genotype and smoking status are
shown separately for men and women in Fig. 2. The effects
on triglyceride are similar between men and women in thatsubjects who carry the  482T allele tended to have higher
triglyceride levels if they were smokers, but not if they had
never been smokers, with the ex-smokers showing an
intermediate effect (genotype/smoking interaction: men,
P= 0.009; women, P= 0.014). However, the numbers in
the  482T/T groups are quite modest, and therefore the
pattern of effect in these groups is somewhat variable. The
effects on triglyceride of the  455T>C were very similar to
the  482C>T, and the smoking interaction terms were
significant in both men (P= 0.02) and women (P= 0.007)
[data not shown].
Associations between the APOC3 variants and NEFA
measures were examined. In the men, but not the women,
Fig. 2. Adjusted mean and 95% CI for triglyceride levels by APOC3  482C>T according to smoking status in men and women. P values correspond to the
significance of the interaction between genotype and smoking on triglyceride levels. Numbers of subjects are shown in the table, corresponding to the columns
in the bar chart.
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smoking) on 30-min NEFA concentrations for both
 482C>T and  455T>C were seen (Table 3). NEFA
levels were higher in homozygous carriers of rare alleles
compared to subjects homozygous for the common alleles
( 482C>T, 26% higher, P= 0.04;  455T>C, 26% higher,
P= 0.006). In addition, there was a significant association
with AUC NEFA for the  455 C>T (C/C, 0.59; T/C, 0.53;
T/T, 0.50: P= 0.02), but results for the AUC for  482C>T
variant were not statistically significant ( 482T/T, 0.6; T/
C, 0.53; C/C, 0.51: P= 0.14). Plots of NEFA for theTable 3
Adjusted means (S.D.) for 30-min NEFA by APOC3  482C>T (n= 502)
and APOC3  455T>C (n= 499) genotypes using data from both phases of
the Ely Study
Men Women
N Mean 95% CI N Mean 95% CI
Lower Upper Lower Upper
 482CC 136 0.347 0.324 0.370 149 0.389 0.363 0.415
 482CT 72 0.364 0.333 0.396 103 0.358 0.327 0.390
 482TT 15 0.439 0.370 0.509 27 0.396 0.333 0.458
P value 0.043 0.296
 455TT 91 0.334 0.306 0.362 104 0.398 0.366 0.429
 455CT 97 0.361 0.334 0.388 132 0.362 0.334 0.390
 455CC 33 0.423 0.376 0.469 38 0.386 0.333 0.439
P value 0.006 0.2397
Data computed using mixed model analysis with 30-min NEFA concen-
tration (at both phases) as outcome variable, adjusted for age and BMI. 482C>T in men and women are shown in Fig. 1C.
Considering the NEFA measures over the time course of
the OGTT, NEFA levels were higher in  482T/T male but
not female subjects (as compared to C/T +C/C subjects).
The  455T>C plot for men was similar to the  482C>T
and is not shown.4. Discussion
Both high fasting insulin (a surrogate for insulin resist-
ance) and a decreased 30-min insulin incremental response
(a surrogate for insulin secretion) are cross-sectionally
associated with glucose intolerance [16] and independently
predict the development of type 2 diabetes [17–19]. In a
previous study of young healthy men (mean age 22), we
found an association with the  482T allele and elevated
AUC insulin and glucose levels after an OGTT [1]. In the
present study of middle-aged men and women (mean age 53
at baseline), we observed a significant association between
the  482T allele and reduced 30-min insulin secretion in
men. This follows the expected pattern of an age-related
decline in glucose tolerance, with hyperinsulinemia, evident
in younger subjects who are adequately compensating for an
impaired glucose homeostatic response, compared with
reduced insulin sensitivity and secretion in older subjects
who are compensating less efficiently and progressing
toward type 2 diabetes. It should be noted though that the
30-min insulin increment is only a surrogate measure for
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secretion and insulin sensitivity. A euglycemic clamp or an
intravenous glucose tolerance test (IVGTT) will be required
to further delineate the exact nature of the defect in these
subjects, though these are difficult to perform in large
numbers of subjects. We have previously evaluated the
association of the  482C>T variant in a British middle-
aged sample (as part of a multi-ethnic study in Wandsworth,
London, UK), and saw a significant increase in fasting
insulin in carriers of the  482T allele in men and women,
but 30-min measures were not available in this study [20].
Thus, in these three studies, EARSII, Wandsworth, and now
the Ely study, we see a significant relationship between the
 482T allele and measures of insulin resistance/secretion in
men, though the particular measure varies between studies.
This may reflect the limitation and overlap between the
various measures of insulin sensitivity/secretion derived
from an OGTT. It is also likely that factors such as diet
and BMI, which are known to affect insulin sensitivity, may
differ between studies and effect our ability to detect the
influence of these genotypes. In addition, a Caucasian group
from London may be more ethnically heterogeneous than
from Ely, a more rural setting.
Other groups have also observed associations between
APOC3 variants and insulin sensitivity. Perez-Jimenez et al.
[21] saw a decrease in insulin sensitivity in men who carried
the S2 allele of the SstI variant (this variant is in strong LD
with the IRE variants) after a high saturated fat diet. This
effect was not seen in the women. Similarly, in the Framing-
ham offspring study, the S2 allele was associated with
elevated fasting insulin concentrations (P < 0.04) in men,
whereas no significant associations were observed in
women [22]. Neither study investigated the IRE variants.
The effects on insulin increment and NEFA levels are
confined to those subjects homozygous for the rare variants,
as were the effects on remnant lipoproteins that we reported
previously [23]. Interestingly, a recent case–control study
investigating angiographically defined atherosclerosis also
showed that homozygosity for the  455C variant was
associated with increased apoCIII levels and an elevated
risk for CAD (OR= 2.5) [24]. The SstI variant did not
confer a significant risk for CAD and the  482C>T was
not investigated in this study (but is in strong LD with the
 455T>C). Thus, it would seem that homozygosity of the
IRE variants is required before a significant effect on insulin
increment/lipids or CAD is observed. As these groups have
relatively low numbers of subjects (though they have two
measures per subject), it is important that these results
should be interpreted with caution until replicated in addi-
tional studies. It is also impossible to tell from the present
study which variant in the IRE is responsible for the
observed effects, given the similarity between the two sets
of results and the lack of statistical justification for differ-
entiating between them.
Even though CAD is the most common cause of death in
patients with diabetes, the mechanism by which dyslipide-mia and type 2 diabetes are linked is unclear. This study
provides some insight into this process. Our results high-
light the synergism between lipid and carbohydrate metab-
olism since we show an association between a measure of
insulin secretion and an APOC3 genotype that is considered
to modulate insulin-mediated regulation of apoCIII and thus
LPL activity.
We can only speculate about a possible mechanism for
the effect of APOC3 promoter variants on insulin secretion.
As apoCIII has been shown to inhibit LPL-mediated lip-
olysis in both in vitro [25] and animal studies [5,26], the
sites of action are likely to involve the tissues where LPL is
responsible for the hydrolysis of triglyceride; particularly
adipose tissue and muscle. However, LPL has also recently
been detected in the pancreatic beta cell [27], where fatty
acids have been shown to be important modulators of
glucose-stimulated insulin secretion (reviewed in Ref.
[28]). As we have found an association with insulin secre-
tion and not fasting insulin (a measure of insulin sensitivity),
the influence of apoCIII on the beta-cell LPL activity is
likely to be of particular importance.
Whatever the mechanism, the observation of signifi-
cantly elevated NEFA levels co-occurring with a reduced
insulin secretion in men supports our prior hypothesis that
elevated NEFA levels could be involved in perturbing
insulin sensitivity and may be the route through which the
APOC3 IRE variants influences insulin/glucose haemostasis
(however, they may also be a consequence). The role of
elevated plasma free fatty acids in the development of
insulin resistance and h-cell dysfunction is now well known
(reviewed in Ref. [29]).
It is possible that these effects observed at the IRE
polymorphisms could be a result of LD with variants in
the newly discovered apoAV gene nearby. However, regres-
sion analysis of haplotypes from the apoA1/C3/A4/A5 locus
suggested that the APOC3  482C>T and the APOA5 W19
variants were largely responsible for the effects on trigly-
ceride observed at this locus and had effects on triglyceride
levels independent from each other [30]. It remains to be
determined whether or not this will also be the case for the
effects on insulin/glucose.
Interestingly, the effects of these IRE variants on insulin/
glucose and lipids differ considerably between men and
women, though this is concordant with the two studies that
showed association between the S2 allele of the SstI site and
insulin sensitivity [21,22]. However, the smoking-depend-
ent effect on triglyceride was common to both men and
women. We have previously shown an almost identical
smoking interaction in a large sample (n = 2745) of healthy
middle-aged men [31]. It is uncertain why the effects of
these variants on glucose homeostasis should occur only in
men. However, a previous analysis of data from individuals
in the Ely Study that investigated the determinants of NEFA
suppression showed considerable differences between men
and women. In men, the strongest association of the area
under the NEFA suppression curve was with the 30-min
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BMI were most closely associated to the area under the
NEFA curve [32]. Therefore, it is plausible to conclude that
associations between insulin secretion and NEFA suppres-
sion are stronger in men than in women in keeping with our
results. Sex-specific differences were also observed in this
cohort for hormone-sensitive lipase variants ( 60C>G),
where an effect on insulin sensitivity was found only in
women and not in men [33].
Thus, we have shown that variation in the APOC3 gene
influences the 30-min insulin increment, a surrogate meas-
ure for insulin secretion and plasma lipid levels in middle-
aged men. Given the predictive value of defective insulin
secretion in determining progression to type 2 diabetes,
these variants may be contributing to the pathogenesis of
this disease. However, as the frequency of these variants did
not differ between NGT and IGT/diabetic subjects, it is
unlikely to be a major susceptibility locus, though the power
to detect susceptibility loci in this study is extremely
limited. These results should be independently validated in
another group with similar characteristics and measures, to
confirm that these effects are robust. Investigation of a type
2 diabetes case-control or family-based association study
will be necessary to more fully evaluate the role of these
variants in this common disease. The recent report showing
a OR of 2.5 for CAD with an IRE variant [24] also
highlights the importance of these variants in CAD, and
the necessity of examining the IRE variants in addition to
the more commonly evaluated SstI variant.Acknowledgements
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